BioCentury
ARTICLE | Finance

Promoting PANAMs

Sage B round to fund clinical data for allosteric modulators in 3 CNS settings

October 28, 2013 7:00 AM UTC

Between a fresh $20 million series B round and a variety of non-dilutive funding sources, Sage Therapeutics Inc. now has enough money to get clinical data for three of its CNS programs.

Existing investors Arch Venture Partners and Third Rock Ventures participated in the financing...